Sana Biotechnology Inc SANA

$1.59 -0.15 (-8.62%)

Valuation

Market cap
476,420,000
Revenue TTM
$0
Net income TTM
$-244,170,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
4,458,900
Avg volume
3,377,606
Day's range
$1.57 – $1.75
Shares out
299,635,000
Stochastic %K
3%
Beta
2.30
Analysts
Strong Buy
Price target
$9.71

Price

Company profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product,...

Show more

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Industry
Biotechnology
Sector
Healthcare
Phone
206 701 7914
Website
https://www.sana.com
Address
188 East Blaine Street, Suite 350, Seattle, United States

Latest news

Stocktwits

WishingWorldWell Nov 20, 7:32 PM
$EOSE $LAES $SANA I'm wondering when an analyst will get the balls to stand up and scream about how a great many small cap stocks are EXTREMELY oversold. For example, EOSE has continued hitting record quarterly revenue and even 8 straight quarters of significantly improving margins and has plenty of cash liquidity on hand, yet has been sold off like they're going out of business at the exact moment when they're RAMPING UP business significantly by moving all of their manufacturing to their new Thorn Hill facility; and they've increased production there to 24 hours a day. Plus, production is way more efficient there which will enable EOS to become profitable by mid 2027. Q4 will show record revenue and improving margins. Revenue has grown over 170% YoY. At least one analyst should become a hero and claim EOSE to be a screaming buy at $1.24 per share
0 replies
BriOnH Nov 20, 5:49 PM
$SANA Why are so many companies trying to replicate Sana's results? https://www.news-medical.net/whitepaper/20261120/Immune-shielded-iPSC-islet-cells-for-diabetes.aspx
0 replies
JRNY13 Nov 20, 4:40 PM
$SANA have you heard? This company has the cure for type 1 di...
0 replies
Dailyfollower Nov 20, 4:08 PM
$SANA 👎 $CDT On the daily chart, RSi is at 15; don't miss the opportunity to buy at the bottom 👍
0 replies
BBraggHillBoys Nov 20, 3:51 PM
$SANA serious financing risk
0 replies
diedhddl Nov 20, 12:28 AM
$SANA Winter is coming.
2 replies
NoJobRob Nov 20, 12:04 AM
$SANA Are we anticipating that there will be an announcement upon IND filing, or only upon clearance? Or has the messaging from Harr been somewhat mixed there? If I recall correctly, it was not really confirmed whether or not there would be 2 announcements, just whether Harr believed it would be "material at the time" or something.
1 replies
BriOnH Nov 19, 8:24 PM 1 replies